Switzerland-based AC Immune SA announced positive interim results from the company’s ongoing Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease.

Biohaven Pharmaceuticals’ third-generation prodrug troriluzole did not show a statistical improvement for patients when compared to those on placebo at the 48-week marker as a symptomatic treatment in mild-to-moderate Alzheimer’s disease (AD).

Biomarkers will be critical to developing precision medicine for Alzheimer’s disease, and phosphorylated tau (P-tau) may enable earlier and more accurate detection, according to Eli Lilly-associated researchers.

Biogen Inc.’s shares slumped as the drugmaker’s chances of getting a regulatory approval for the experimental Alzheimer’s treatment aducanumab suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.

A panel of outside advisers to the U.S. Food and Drug Administration voted that a potential Alzheimer’s treatment from Biogen Inc. has not been proven to slow progression of the disease, a sharp rebuke to agency staff who had praised the drug.

Biogen Inc. showed “exceptionally persuasive” evidence that the company’s experimental Alzheimer’s disease drug aducanumab is effective, U.S. Food and Drug Administration staff said, elevating chances of a swift approval and sending company shares soaring.

U.S. health experts this week will decide whether to recommend approval for Biogen Inc.’s experimental Alzheimer’s drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if the antibody aducanumab works.

Researchers with Pfizer and IBM developed an artificial intelligence (AI) model that they claim can predict the eventual onset of Alzheimer’s disease with 71% accuracy based on a language sample.

Nearly 300,000 more people have died in the United States in 2020 during the coronavirus pandemic than expected based on historical trends, with about two-thirds of the deaths due to Covid-19 illnesses, according to a report.

Vaccinex announced topline data from the early manifest treatment arm of the company’s Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease (HD).